Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for CSL BEHRING LLC · Biotherapeutic company providing recombinant and plasma-derived products.

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Pennsylvania

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Medicare/Medicaid

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Health Issues

Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing. Issues regarding plasma-based therapies.

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S.

Trade (domestic/foreign)

Issues related to tariffs.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem